EP4267109A1 - A non-micronized bilastine composition - Google Patents
A non-micronized bilastine compositionInfo
- Publication number
- EP4267109A1 EP4267109A1 EP21819492.6A EP21819492A EP4267109A1 EP 4267109 A1 EP4267109 A1 EP 4267109A1 EP 21819492 A EP21819492 A EP 21819492A EP 4267109 A1 EP4267109 A1 EP 4267109A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- composition
- weight
- bilastine
- pyrrolidone
- based polymer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 193
- ACCMWZWAEFYUGZ-UHFFFAOYSA-N bilastine Chemical compound N=1C2=CC=CC=C2N(CCOCC)C=1C(CC1)CCN1CCC1=CC=C(C(C)(C)C(O)=O)C=C1 ACCMWZWAEFYUGZ-UHFFFAOYSA-N 0.000 title claims abstract description 107
- 229960004314 bilastine Drugs 0.000 title claims abstract description 106
- 238000000034 method Methods 0.000 claims abstract description 61
- 239000002245 particle Substances 0.000 claims abstract description 58
- 229920000642 polymer Polymers 0.000 claims abstract description 49
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 47
- 230000008569 process Effects 0.000 claims abstract description 41
- 239000003937 drug carrier Substances 0.000 claims abstract description 33
- 238000009826 distribution Methods 0.000 claims abstract description 27
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 claims abstract description 18
- 206010020751 Hypersensitivity Diseases 0.000 claims abstract description 10
- 201000010099 disease Diseases 0.000 claims abstract description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 10
- 230000001404 mediated effect Effects 0.000 claims abstract description 10
- 229960001340 histamine Drugs 0.000 claims abstract description 9
- 238000011282 treatment Methods 0.000 claims abstract description 9
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 claims description 39
- 239000000945 filler Substances 0.000 claims description 35
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical group C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 30
- 239000000314 lubricant Substances 0.000 claims description 29
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 25
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 25
- 229960000913 crospovidone Drugs 0.000 claims description 21
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims description 16
- 239000011230 binding agent Substances 0.000 claims description 14
- 239000007884 disintegrant Substances 0.000 claims description 10
- 230000005855 radiation Effects 0.000 claims description 10
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims description 4
- -1 glidant Substances 0.000 claims description 4
- 238000002636 symptomatic treatment Methods 0.000 claims description 4
- 208000024780 Urticaria Diseases 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 230000001932 seasonal effect Effects 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 abstract description 21
- 239000003826 tablet Substances 0.000 description 60
- 238000004090 dissolution Methods 0.000 description 24
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 16
- 230000000052 comparative effect Effects 0.000 description 14
- 238000002156 mixing Methods 0.000 description 14
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 14
- 239000004480 active ingredient Substances 0.000 description 13
- 239000004615 ingredient Substances 0.000 description 11
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 11
- 239000008186 active pharmaceutical agent Substances 0.000 description 9
- 239000002552 dosage form Substances 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- 239000000463 material Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 230000008570 general process Effects 0.000 description 7
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 238000012216 screening Methods 0.000 description 6
- 235000002639 sodium chloride Nutrition 0.000 description 6
- 238000009472 formulation Methods 0.000 description 5
- 230000036470 plasma concentration Effects 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 230000008901 benefit Effects 0.000 description 4
- FFBHFFJDDLITSX-UHFFFAOYSA-N benzyl N-[2-hydroxy-4-(3-oxomorpholin-4-yl)phenyl]carbamate Chemical compound OC1=C(NC(=O)OCC2=CC=CC=C2)C=CC(=C1)N1CCOCC1=O FFBHFFJDDLITSX-UHFFFAOYSA-N 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 239000012738 dissolution medium Substances 0.000 description 4
- 235000003599 food sweetener Nutrition 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 238000005461 lubrication Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000000178 monomer Substances 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 239000003765 sweetening agent Substances 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229920000881 Modified starch Polymers 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 238000004132 cross linking Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 235000019426 modified starch Nutrition 0.000 description 3
- 238000000634 powder X-ray diffraction Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000007873 sieving Methods 0.000 description 3
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 2
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 229920002785 Croscarmellose sodium Polymers 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 239000002033 PVDF binder Substances 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 238000005054 agglomeration Methods 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 2
- 239000001099 ammonium carbonate Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000012296 anti-solvent Substances 0.000 description 2
- 235000019568 aromas Nutrition 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 229920006037 cross link polymer Polymers 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000000938 histamine H1 antagonist Substances 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 230000001050 lubricating effect Effects 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000003921 particle size analysis Methods 0.000 description 2
- 238000000517 particles from gas-saturated solution Methods 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 description 2
- 229940069328 povidone Drugs 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 238000001046 rapid expansion of supercritical solution Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 2
- 239000008109 sodium starch glycolate Substances 0.000 description 2
- 229920003109 sodium starch glycolate Polymers 0.000 description 2
- 229940079832 sodium starch glycolate Drugs 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 1
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical group O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 235000011034 Rubus glaucus Nutrition 0.000 description 1
- 244000235659 Rubus idaeus Species 0.000 description 1
- 235000009122 Rubus idaeus Nutrition 0.000 description 1
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 239000000619 acesulfame-K Substances 0.000 description 1
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 229920003090 carboxymethyl hydroxyethyl cellulose Polymers 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229960005168 croscarmellose Drugs 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- QGGZBXOADPVUPN-UHFFFAOYSA-N dihydrochalcone Chemical compound C=1C=CC=CC=1C(=O)CCC1=CC=CC=C1 QGGZBXOADPVUPN-UHFFFAOYSA-N 0.000 description 1
- PXLWOFBAEVGBOA-UHFFFAOYSA-N dihydrochalcone Natural products OC1C(O)C(O)C(CO)OC1C1=C(O)C=CC(C(=O)CC(O)C=2C=CC(O)=CC=2)=C1O PXLWOFBAEVGBOA-UHFFFAOYSA-N 0.000 description 1
- 238000007922 dissolution test Methods 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 239000012728 immediate-release (IR) tablet Substances 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000000832 lactitol Substances 0.000 description 1
- 235000010448 lactitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 1
- 229960003451 lactitol Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- 229940037627 magnesium lauryl sulfate Drugs 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 235000012245 magnesium oxide Nutrition 0.000 description 1
- 229940057948 magnesium stearate Drugs 0.000 description 1
- HBNDBUATLJAUQM-UHFFFAOYSA-L magnesium;dodecyl sulfate Chemical compound [Mg+2].CCCCCCCCCCCCOS([O-])(=O)=O.CCCCCCCCCCCCOS([O-])(=O)=O HBNDBUATLJAUQM-UHFFFAOYSA-L 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 239000008185 minitablet Substances 0.000 description 1
- ARGKVCXINMKCAZ-UZRWAPQLSA-N neohesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O[C@H]3[C@@H]([C@H](O)[C@@H](O)[C@H](C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UZRWAPQLSA-N 0.000 description 1
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920006267 polyester film Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000004886 process control Methods 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000012798 spherical particle Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000003445 sucroses Chemical class 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 238000004808 supercritical fluid chromatography Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Definitions
- the present invention relates to a novel composition comprising non-micronized bilastine, a preparation process thereof and the use of the composition in the treatment of histamine-mediated disease processes and allergic reactions.
- Bilastine is the international common name of 4-[2-[4-[1 -(2-ethoxyethyl)-1 h-benzimidazol-2-yl]-1 - piperidinyl)ethyl]-o,a-dimethyl-benzeneacetic acid, whose structure corresponds to the compound of formula (I):
- Bilastine is a selective H1 receptor antagonist, meaning that it is useful for treating histamine-mediated disease processes and allergic reactions, and especially for treating rhinoconjunctivitis and urticaria.
- Bilastine as a product perse, as well as the preparation and use thereof as an H1 receptor antagonist has been described in the European patent number EP0818454B1 .
- the European patent EP1505066B1 describes three crystalline forms of bilastine. Specifically, it describes the crystalline forms 1, 2 and 3 of bilastine, which are characterized by the infrared absorption spectrum and crystallographic parameters in the case of form 1.
- preparation methods of crystalline form 1 from a mixture of crystalline forms 2 and 3 are described. However, crystalline forms 2 and 3 of bilastine are easily converted into crystalline form 1.
- the European patent application EP16829901 A1 describes other crystalline forms of bilastine including Eta crystalline form which is characterized by X-ray diffractogram.
- Bilastine is actually present in the market with the commercial drug name Bilaxten, which is in form of inmediate-release and orodispersible tablets. Particularly, Bilaxten contains crystalline form 1 of bilastine in micronized form, having a particle size distribution D90 about 6.8 pm.
- the different solid forms of a pharmaceutical active ingredient may have different characteristics and offer certain advantages, for example, with respect to stability, bioavailability, ease of the formulation and ease of administration, among others. Since some solid forms are more suitable for one type of formulation, and other forms for other different formulations, the development of novel solid forms makes it possible to improve the characteristics of pharmaceutical formulations that comprise them. Furthermore, depending on therapeutic indications, one or another pharmaceutical formulation may be preferable.
- the particle size of the active ingredient may be also critical for having the appropriate dissolution profile and bioavailabilty.
- a reduction of the particle size of the active ingredient may be advantegeous for increasing its therapeutic efficacy.
- Micronization is the process of reducing the average diameter of a solid material's particles.
- the term micronization refers to the reduction of average particle diameters to the micrometer range.
- micronized active ingredients for the preparation of solid pharmaceutical compositions entails some processability problems.
- the first problems is related to wettability and reagglomeration by electrostatic phenomena.
- a mixture containing micronized active ingredients is compressed into tablets, there is a possibility of agglomeration of the micronized particles together within the tablet due to their high surface area and high surface free energy during compression; and also a modification of the physical and chemical properties of the ingredients including the active ingredients and the excipients or carriers.
- a change of the polymorphisms of the active ingredient may occur during the micronization process or during its compression, resulting in a possible modification of crucial bioavailability properties (such as stability, dissolution and absorption).
- the second problem is that micronization processes employ higher financial resources and therefore their production is more costly, due to an extra process needed to obtain the desired particle size, affecting the yield and generating more problems from a security and process control point of view. Therefore, from what is known in the art it is derived that there is still the need of providing compositions comprising non-micronized bilastine having the apropriate dissolution rate and bioavailability by an easy industrially-scaling up and reproducible process.
- compositions comprising a therapeutically effective amount of non-micronized bilastine in combination with a pyrrolidone-based polymer, allows having comparable pharmacokinetic parameters on bioavailability (e.g. C m ax, AUCo-t, AUCo- ⁇ , AUCO-T.SS, C m ax, ss, and Cmin. ss) as commercially available Bilaxten containing bilastine micronized.
- bioavailability e.g. C m ax, AUCo-t, AUCo- ⁇ , AUCO-T.SS, C m ax, ss, and Cmin. ss
- composition of the invention which comprises the combination of a therapeutically effective amount of bilastine having a particle size distribution D90 from 15 to 90 pm with a pyrrolidone-based polymer allows having the appropriate dissolution rate and availability for being used in therapy and being considered equivalent to Bilaxten which contains micronized bilastine.
- compositions of the present invention containing non-micronized bilastine can be prepared by a costless, simple, industrially scale-up and reproducible method without the processability problems disclosed in the state of the art associated to the use of micronized active ingredients (such as wettability and reagglomeration by electrostatic phenomena).
- a first aspect of the invention relates to a composition
- a composition comprising: a therapeutically effective amount of bilastine having a particle size distribution D90 from 15 to 90 pm measured by laser diffraction; and a pyrrolidone-based polymer; together with one or more pharmaceutically acceptable excipients or carriers.
- the second aspect of the invention relates to a preparation process of the composition of the first aspect of the invention.
- the third aspect of the invention relates to the use of the composition of the first aspect of the invention in the treatment of histamine-mediated disease processes and allergic reactions.
- FIG. 1 pattern of X-ray powder diffraction (intensity (counts) vs. angle 2-theta (°)) of crystalline form Eta of bilastine.
- FIG. 2 pattern of X-ray powder diffraction (intensity (counts) vs. angle 2-theta (°)) of crystalline form 1 of bilastine.
- any ranges given include both the lower and the upper end-points of the range. Ranges given, such as temperatures, times, weights, and the like, should be considered approximate, unless specifically stated.
- the term “about” or “around” as used herein refers to a range of values ⁇ 10% of a specified value. For example, the expression “about 15” includes ⁇ 10% of 15, i.e. from 13.5 to 16.5.
- percentage (%) by weight refers to the percentage of each ingredient of the composition in relation to the total weight of the composition.
- the composition comprises a therapeutically effective amount of bilastine having a particle size distribution D90 from 15 to 90 m.
- a "therapeutically effective amount” of bilastine relates to the amount of bilastine that provides a therapeutic effect after the administration thereof.
- the therapeutically effective amount of bilastine is from about 5 to 50 mg, particularly from about 10 to 40 mg, particularly from about 10 to 30 mg and particularly from about 10 to 20 mg.
- the bilastine in the compositions of the invention is not micronized, and particular, the particle size distribution D90 of bilastine is from about 15 to 90 pm. In an embodiment, the particle size distribution D90 of bilastine is from about 25 to 80 pm, particularly from about 25 to 75 pm.
- particle size refers to the size of the particles measured in pm. The measurement was performed with an appropriate apparatus by conventional analytical techniques such as, for example, laser diffraction. In the present invention the particle size was measured by a Mastersizer 3000 particle size analyzer. Such apparatus uses a technique of laser diffraction to measure the size of particles. It operates by measuring the intensity of light scattered, as a laser beam passes through a dispersed particles sample.
- This data is then analyzed using the general purpose model to calculate the size of the particles that created the scattering pattern, assuming a spherical particle shape.
- microscopic determination utilizing a scanning electron microscope (SEM) may be used. But laser diffraction is preferred.
- particle size distribution or “PSD” have the same meaning and are used interchangeably. They refer to the percentage of the particles within a certain size range.
- D90 refers to the value of particle size distribution where at least 90% of the particles have a size less or equal to the given value.
- D50 refers to the value of particle size distribution where at least 50% of the particles have a size less or equal to the given value.
- a particle size distribution D90 from about 15 to 90 m means that the 90% of the particles of bilastine have a size less or equal to the given value within the range from about 15 to 90 pm.
- composition of the invention also comprises a pyrrolidone-based polymer.
- pyrrolidone-based polymer means that the chemical structure of the monomer of the backbone of the polymer, from which the pyrrolidone-based polymer is made, contains a pyrrolidone.
- a "pyrolidonebased polymer” refers to a polymer that comprises more than 50% by weight of polymerized pyrrolidone units (also named monomer).
- the composition is one wherein the pyrrolidone-based polymer comprises 1 -vinyl-2- pyrrolidone units, which mean that the pyrrolidone-based polymer is a polyvinylpyrrolidone.
- the terms “polyvinylpyrrolidone”, “polyvidone”, “povidone” and “PVP” have the same meaning and they are used interchangeable.
- the polyvinylpyrrolidone is the polymer made from the monomer N- vinylpyrroiidone.
- Polyvinylpyrrolidone is the common name of the compound 1-ethenylpyrrolidin-2-one with the CAS number 9003-39-8 having the following structure:
- the composition is one wherein the pyrrolidone-based polymer is a cross-linked polyvinylpyrrolidone.
- the terms “cross-linked polyvinylpyrrolidone”, “polyvinylpolypyrrolidone”, “polyvinyl polypyrrolidone”, “PVPP”, “crospovidone” and “crospolividone” have the same meaning and they are used interchangeable.
- the crospovidone is a crosslinked polymer made from the monomer N- viny Ipy rrolidone.
- Crospovidone is the common name of the crosslinked polyvinylpyrrolidone (PVP) named crosslinked 1 -ethenylpyrrolidin-2-one with has the CAS number 25249-54-1.
- cross-linked refers to the use of cross-links to promote a difference in the physical properties of the polymers.
- cross-links refers to bonds that link one polymer chain to another or differents parts of the same polymer and these bonds can be covalent or ionic bonds.
- cross-linker or “cross-linking agent” refers to compounds having the ability to cross-link the polymer chains.
- percentage of crosslinking refers to the amount of cross-links present in the polymer.
- the pyrrolidone-based polymer may be any cross-linked polyvinylpyrrolidone with any percentage of crosslinking as measured by ASTM D2765 or by ASTM F2214.
- the composition comprises from 1 to 10 % by weigth of the pyrrolidone-based polymer. In an embodiment, the composition comprises from 1 and 8 % by weigth of the pyrrolidone-based polymer. In an embodiment, the composition comprises from 2 and 8 % by weigth of the pyrrolidone-based polymer. In an embodiment, the composition comprises from 3 and 5 % by weigth of the pyrrolidone-based polymer.
- the composition comprises bilastine having an X-ray diffractogram that comprises characteristic peaks at 8.4; 9.6; 12.2; 13.2; 15.1; and 19.2 ⁇ 0.2 degrees 2 theta measured with an X-ray diffractometer with Cu Ko radiation (1.5418 A) called crystalline Eta form of bilastine.
- the composition comprises Eta crystalline form of bilastine which further contains characteristic peaks at 19.7; 20.3; 21 .5; and 23.4 ⁇ 0.2 degrees 2 theta measured with an X-ray diffractometer with Cu Ko radiation
- the composition comprises Eta crystalline form of bilastine which further also contains peaks at 14.0; 16.8; 17.5; 18.2 and 25.5 ⁇ 0.2 degrees 2 theta measured with an X-ray diffractometer with Cu Ko radiation (1.5418 A).
- the composition comprises Eta crystalline form of bilastine having the X-ray diffractogram shown in FIG. 1.
- the composition comprises Eta crystalline form of bilastine characterized in that it shows the pattern of peaks, expressed in units of 2 theta degrees, 20 (°), in the X-ray powder diffractogram shown in the following table:
- the Eta crystalline form of bilastine is prepared following the processes disclosed in the European patent application EP16829901.
- the process for the preparation of the Eta crystalline form of bilastine comprising transforming the form 1 of bilastine into the Eta crystalline form, which comprises dispersing crystalline form 1 in water during the time needed for the transformation into the Eta crystalline form of bilastine of said dispersion to take place.
- the composition comprises bilastine having an X-ray diffractogram that comprises characteristic peaks at 12.51; 16.35; 17.24, 19.99 and 21.20 ⁇ 0.2 degrees 2 theta measured with an X-ray diffractometer with Cu Ko radiation (1.5418 A) called crystalline Form I of bilastine.
- the composition comprises crystalline Form I of bilastine which further contains characteristic peaks at 10.65; 12.64, 15.58 and 25.00 ⁇ 0.2 degrees 2 theta measured with an X-ray diffractometer with Cu Ko radiation (1.5418 A).
- the composition comprises crystalline Form I of bilastine which further also contains peaks at 14.14, 14.33, 1 .48, 23.40 ⁇ 0.2 degrees 2 theta measured with an X-ray diffractometer with Cu Ko radiation (1.5418 A).
- the composition comprises crystalline Form I of bilastine having the X-ray diffractogram shown in FIG. 2.
- the composition comprises crystalline Form I of bilastine characterized in that it shows the pattern of peaks, expressed in units of 2 theta degrees, 20 (°), in the X-ray powder diffractogram shown in the following table:
- the crystalline form I of bilastine is prepared following the processes disclosed in the European patent EP1505066B1.
- the process for the preparation of the crystalline Form 1 of bilastine comprises dispersing crystalline form 1 in water during the time needed for the transformation into the Eta crystalline form of bilastine of said dispersion to take place.
- composition of the present invention comprise one or more pharmaceutically acceptable excipients or carriers.
- pharmaceutically acceptable excipients or carriers refers to that excipients or carriers suitable for use in the pharmaceutical technology for preparing compositions with medical use. Said excipients or carriers must be pharmaceutically acceptable in the sense that they must be compatible with the rest of the ingredients of the pharmaceutical composition. They must also be suitable for use in contact with human or animal tissues or organs without showing excessive toxicity, irritation, allergic response, immunogenicity or other problems or complications relating to a reasonable risk/benefit ratio.
- compositions of the invention can be formulated in any form that includes any single unit dosage form and any multiple unit dosage forms.
- single unit encompasses one entity such as a single tablet, a single granule, and a single pellet.
- single unit dosage form defines a dosage form which consists only of one unit which contains the effective amount of bilastine.
- multiple unit dosage form defines a dosage from which consists of more than one unit which contains the effective amount of bilastine.
- the multiple unit dosage forms are based on subunits such as granules, pellets or minitablets. They are usually delivered in hard capsules or transformed into tablets. Thus, it is also part of the invention a unit dosage form which comprises the composition of the present invention.
- the unit dosage from which comprises the composition of the present invention is a single unit dosage form. In an embodiment, the unit dosage from which comprises the composition of the present invention is a multiple unit dosage form.
- the appropriate excipients and/or carriers, and their amounts, can readily be determined by those skilled in the art according to the type of formulation being prepared.
- the pharmaceutically acceptable excipients or carriers are selected from the group consisting of selected from the group consisting of diluent, lubricant, binder, glidant, disintegrant and mixtures thereof.
- filler and “diluent” have the same meaning and are used interchangeably. They refer to any pharmaceutically acceptable excipient or carrier (material) that fill out the size of a composition, making it practical to produce and convenient for the consumer to use.
- Materials commonly used as filler include calcium carbonate, calcium phosphate, dibasic calcium phosphate, tribasic calcium sulfate, calcium carboxymethyl cellulose, cellulose, cellulose products such as microcrystalline cellulose and its salts, dextrin derivatives, dextrin, dextrose, fructose, lactitol, lactose, starches or modified starches, magnesium carbonate, magnesium oxide, maltitol, maltodextrins, maltose, mannitol, sorbitol, starch, sucrose, sugar, xylitol, erythritol and mixtures thereof.
- the composition of the invention is one wherein the pharmaceutically acceptable excipients or carriers comprises one or more fillers. In an embodiment, the composition of the invention is one wherein the pharmaceutically acceptable excipients or carriers comprises one or more fillers selected from the group consisting of microcrystalline cellulose or sugar alcohols like mannitol. In an embodiment, the composition of the invention is one wherein the pharmaceutically acceptable excipients or carriers comprise one or more filler in an amount from about 35 to 90% by weight of the composition, particularly from about 50 to 90% by weight of the composition, particularly from about 70 to 90% by weight of the composition.
- lubricant refers to a substance that prevents composition ingredients from clumping together and from sticking to the tablet punches or capsule filling machine and improves flowability of the composition mixture.
- Materials commonly used as a lubricant include sodium oleate, sodium stearate, sodium benzoate, sodium stearate, sodium chloride, stearic acid, sodium stearyl fumarate, calcium stearate, magnesium stearate, magnesium lauryl sulfate, sodium stearyl fumarate, sucrose esters or fatty acid, zinc, polyethylene glycol, talc and mixtures thereof.
- the presence of a lubricant is particularly preferred when the composition is a tablet to improve the tableting process.
- the composition of the invention is one wherein the pharmaceutically acceptable excipients or carriers comprises one or more lubricants selected from the group consisting of magnesium stearate, ascorbic acid and sodium stearyl fumarate. In an embodiment, the composition of the invention is one wherein the pharmaceutically acceptable excipients or carriers comprise one or more lubricants in an amount from 0.1 to 5% by weight of the composition, particularly from 0.5 to 5% by weight of the composition, particularly from about 0.5 to 3% by weight of the composition.
- binder refers to any pharmaceutically acceptable compound having binding properties.
- Materials commonly used as binders include povidone such as polyvinylpyrrolidone K30, ethyl cellulose polymers, methylcellulose polymers, hydroxyethyl cellulose, hydroxypropyl cellulose, L-hydroxypropyl cellulose (low substituted), hydroxypropylmethyl cellulose (HPMC), sodium carboxymethyl cellulose, carboxymethylene, carboxymethylhydroxyethyl cellulose and other cellulose derivatives, starches or modified starches and mixture thereof.
- the composition of the invention is one wherein the pharmaceutically acceptable excipients or carriers comprise one or more binders.
- the composition of the invention is one wherein the pharmaceutically acceptable excipients or carriers comprise one or more binders selected from the group consisting of polyvinylpyrrolidone, ethyl cellulose and hydroxypropylmethyl cellulose.
- the composition of the invention is one wherein the pharmaceutically acceptable excipients or carriers comprise one or more binders in an amount from 0 to 10% by weight of the composition, particularly from 1 to 10% by weight of the composition, particularly from 1 to 7% by weight of the composition, particularly from about 2.5 to 6% by weight of the composition.
- glidant refers to a substance which improves the flow characteristics of powder mixtures in the dry state.
- Materials commonly used as a glidant include magnesium stearate, colloidal silicon dioxide or talc.
- the composition of the invention is one wherein the pharmaceutically acceptable excipients or carriers comprises one or more glidants.
- the composition of the invention is one wherein the pharmaceutically acceptable excipients or carriers comprises one or more glidants selected from the group consisting of colloidal silicon dioxide and talc.
- the composition of the invention is one wherein the pharmaceutically acceptable excipients or carriers comprise one or more glidants in an amount from 0 to 5% by weight of the composition, particularly from 0.1 to 5% by weight of the composition, particularly from 0.2 to 5% by weight of the composition, particularly from about 0.5 to 3% by weight of the composition.
- disintegrant refers to a substance that expand and dissolve when wet causing the tablet to break apart in the body and release the active ingredient for absorption.
- Materials commonly used as disintegrants include cross-linked polymers like, for example, crospovidone and croscarmellose sodium, and modified starches like sodium starch glycolate.
- the composition of the invention is one wherein the pharmaceutically acceptable excipients or carriers further comprises at least one or more disintegrants differents from pyrrolidone-based polymer. In an embodiment, the composition of the invention is one wherein the pharmaceutically acceptable excipients or carriers comprises at least one disintegrant different from a pyrrolidone-based polymer selected from the group consisting of croscarmellose and sodium starch glycolate. In an embodiment, the composition of the invention is one wherein the pharmaceutically acceptable excipients or carriers comprise one or more disintegrants different from a pyrrolidone-based polymer in an amount from 0 to 10, particularly from 0 to 5% by weight, particularly from about 0.1 to 5 % by weight of the composition.
- composition of the present invention may contain other ingredients, such as colorants, sweeteners, aromas, and other components known in the state of the art for use in solid formulations.
- sweeteners may be selected from the group consisting of sucralose, acesulfame K, aspartame, neohesperidin and dihydrochalcone.
- Aromas may be selected from the group consisting of grape aroma, strawberry aroma and raspberry aroma.
- the composition of the present invention comprises: a therapeutically effective amount of bilastine having a particle size distribution D90 from 15 to 90 pm; and from 1 to 10 % by weight of a pyrrolidone-based polymer, particularly crospovidone; from 35 to 90 % by weight of a filler; from 0 to 5 % by weight of a glidant; from 0 to 10 % by weight of binder; from 0 to 10 % by weight of a disintegrant different from a pyrrolidone-based polymer; from 0.1 to 5 % by weight of a lubricant; and optionally other pharmaceutically acceptable excipients or carriers; being the sum of the components up to 100% by weight of the composition.
- the composition of the present invention is in a form of tablet.
- the composition of the present invention is form of a tablet and comprises: a therapeutically effective amount of bilastine having a particle size distribution D90 from 15 to 90 pm; and from 1 to 10 % by weight of a pyrrolidone-based polymer, particularly crospovidone; from 35 to 90 % by weight of a filler; from 0 to 5 % by weight of a glidant; from 0 to 10 % by weight of binder; from 0 to 10 % by weight of a disintegrant different from a pyrrolidone-based polymer; from 0.1 to 5 % by weight of a lubricant; and optionally other pharmaceutically acceptable excipients or carriers; being the sum of the components up to 100% by weight of the composition.
- composition of the present invention is in a form of immediate release tablet and an orodispersible tablet (abbreviated as ODT).
- the composition of the present invention is in a form immediate release tablet.
- immediate release composition refers to a composition which releases the active ingredient substantially immediately upon contact with gastric juices and will result in substantially complete dissolution within about 1 hour.
- Immediate release (IR) components can also be referred to as instant release.
- immediate release refers to the composition which delivers the active ingredient over a period of time less than 1 hour.
- the composition of the present invention is in form of an immediate release tablet comprising: a therapeutically effective amount of bilastine having a particle size distribution D90 from 15 to 90 pm; and from 1 to 10 % by weight of a pyrrolidone-based polymer, particularly crospovidone; from 35 to 90 % by weight of a filler; from 0.1 to 5 % by weight of a glidant; from 0.1 to 5 % by weight of a lubricant; and optionally other pharmaceutically acceptable excipients or carriers; being the sum of the components up to 100% by weight of the composition.
- the composition of the present invention is in form of an immediate release tablet comprising: a therapeutically effective amount of bilastine having a particle size distribution D90 from 15 to 90 pm; and from 2 to 8 % by weight of a pyrrolidone-based polymer, particularly crospovidone; from 50 to 90 % by weight of a filler; from 0.2 to 5 % by weight of a glidant; from 0.5 to 5 % by weight of a lubricant; and optionally other pharmaceutically acceptable excipients or carriers; being the sum of the components up to 100% by weight of the composition
- the composition of the present invention is in form of an immediate release tablet comprising: a therapeutically effective amount of bilastine having a particle size distribution D90 from 15 to 90 pm; and from 3 to 5 % by weight of a pyrrolidone-based polymer, particularly crospovidone; from 70 to 90 % by weight of a filler; from 0.5 to 3 % by weight of a glidant; from 0.5 to 3 % by weight of a lubricant; and optionally other pharmaceutically acceptable excipients or carriers; being the sum of the components up to 100% by weight of the composition
- the composition is in form of a orodispersible tablet (ODT).
- ODT orodispersible tablet
- orodispersible tablet refers to non-coated tablets for placing in the mouth which disintegrate quickly before they are swallowed.
- the orodispersible tablet of the present invention is advantageously used in cases where administration without water is necessary, cases of administration to patients who have difficulty in swallowing tablets, or cases of administration to the elderly or to children where there is a fear of blocking the throat if it is unusual tablet form.
- the composition of the present invention is in form of an orodispersible tablet comprising: a therapeutically effective amount of bilastine having a particle size distribution D90 from 15 to 90 pm; and from 1 to 10 % by weight of a pyrrolidone-based polymer, particularly crospovidone; from 35 to 90 % by weight of a filler; from 1 to 10 % by weight of a binder; from 0.1 to 5 % by weight of a lubricant; and optionally other pharmaceutically acceptable excipients or carriers; being the sum of the components up to 100% by weight of the composition.
- the composition of the present invention is in form of an orodispersible tablet comprising: a therapeutically effective amount of bilastine having a particle size distribution D90 from 15 to 90 pm; and from 2 to 8 % by weight of a pyrrolidone-based polymer, particularly crospovidone; from 50 to 90 % by weight of a filler; from 1 to 7 % by weight of a binder; from 0.5 to 5 % by weight of a lubricant; and optionally other pharmaceutically acceptable excipients or carriers; being the sum of the components up to 100% by weight of the composition.
- the composition of the present invention is in form of an orodispersible tablet comprising: a therapeutically effective amount of bilastine having a particle size distribution D90 from 15 to 90 pm; and from 3 to 5 % by weight of a pyrrolidone-based polymer, particularly crospovidone; from 70 to 90 % by weight of a filler; from 2.5 to 6 % by weight of a binder; from 0.5 to 3 % by weight of a lubricant; and optionally other pharmaceutically acceptable excipients or carriers being the sum of the components up to 100% by weight of the composition.
- the process for the preparation of the immediate release tablets of the present invention comprises: a) preparing a pre-mixture comprising bilastine or a pharmaceutically acceptable salt thereof, Crospovidone and a part of the filler (particularly about 20% of the total amount of the filler); f) optionally, sieving the pre-mixture obtained in step a) and each one of the remaining excipients (including the remaining quantity of the filler) separately by a sieve having a sieve diameter from 750 to 1250 pm; b) mixing the pre-mixture obtained in step a) with the remaining excipients including the crospovidone and except for the lubricant; c) adding the lubricant to the mixture obtained in step b); and d) compressing the mixture obtained in step (c) to form tablets; and (e) optionally, coating the tablets obtained in step (d).
- the process for the preparation of the orodispersible tablets of the present invention comprises: a') preparing a first pre-mixture comprising the flavour, the sweetener and a part of the filler (particularly about 10% of the total amount of the filler); a”) preparing a second pre-mixture comprising bilastine or a pharmaceutically acceptable salt thereof, Crospovidone and a part of the remaining part of the filler (particularly about 40-50% of the total amount of the filler); f) optionally, sieving the first and the second pre-mixture obtained in step a') and a”), and each one of the remaining excipients (including the remaining quantity of the filler) separately by a sieve having a sieve diameter from 750 to 1250 pm; b') mixing the first and the second pre-mixture with the remaining excipients including the crospovidone the remaining quantity of the filler and except for the lubricant; c') adding the lubricant to the mixture obtained in step b’
- each one of the steps (a), (a') and (a”) of the process for preparation of the composition of the invention is performed at room temperature. In an embodiment, each one of the steps (a), (a') and (a”) of the process for preparation of the composition of the invention is performed manually at lab step or in a double cone or tumbler mixer at industrial scale.
- each one of the steps (b), (b'), (c) and (c') of the process for preparation of the composition of the invention is performed at room temperature. In an embodiment, each one of the steps (b), (b'), (c) and (c’) of the process for preparation of the composition of the invention is performed in a double cone or tumbler mixer.
- the process comprises step (f) or (f).
- each one of steps (f) or (f) are performed by the use of a sieve of 1000 m for sieving the pre-mixtures, mixture and excipients excpet for the lubricant which is sieve throught a sieve of 250 pm of diameter.
- the compressing steps (d) and (d’) of the process for preparation of the composition of the invention is performed using an eccentric tableting machine for lab-scale process and rotary tableting machine for industrial scale. In an embodiment, the compressing steps (d) and (d’) of the process for preparation of the composition of the invention is performed in order to obtain tablets having a hardness about 55 to 95N.
- composition of the invention allows having the appropriate dissolution rate and availability for being used in therapy and considered equivalent to Bilaxten which include micronized bilastine.
- the composition of the invention is an immediate release tablet which exhibits a dissolution profile according to which at least 85% by weight of the bilastine or a pharmaceutically acceptable salt thereof is dissolved in 15 min, wherein: the dissolution profile is measured using a USP type I apparatus (basket), placing the composition in 900mL of phosphate buffer having pH 6.8, at 37°C and 50 rpm.
- the composition of the invention is an orodispersible tablet which exhibits a dissolution profile according to which at least 85% by weight of the bilastine or a pharmaceutically acceptable salt thereof is dissolved in 15 min, wherein: the dissolution profile is measured using a USP type I apparatus (basket), placing the composition in 900mL of phosphate buffer having pH 6.8, at 37°C and 50 rpm.
- a skilled person must differencials between disintegration (according to the Ph. Eur. 2.9.1. is 3 minutes) and dissolution profile.
- the composition of the invention exhibits a maximum plasma concentration (Cmax) and an area under the time/plasma concentration curve from time 0 to 36 hours (AUG (0-36)) from 80 to 125% refering to the Bilaxten reference product, in a confidence interval of 90% .
- Cmax refers to the maximum concentration of bilastine in the blood following a single-dose administration of the composition.
- AUG refers to the area under the time/plasma concentration curve after an oral single-dose administration of the composition of the present invention.
- AUCO-infinity denotes the area under the plasma concentration versus time curve from time 0 to infinity
- AUCo-t denotes the area under the plasma concentration versus time curve from time 0 to time t.
- composition of the invention in treatment of histamine- mediated disease processes and allergic reactions.
- This aspect could be also formulated as the use of a composition of the invention as defined above for the preparation of a medicament for the prophylaxis and/or treatment of the histamine-mediated disease processes and allergic reactions. It also relates to a method for the prophylaxis and/or treatment of a mammal suffering or is susceptible to suffer from a histamine-mediated disease processes and allergic reactions, wherein the method comprises administering to said mammal an effective amount of the composition of the present invention.
- the histamine-mediated disease processes and allergic reactions are selected from the group consisting of the symptomatic treatment of seasonal allergic rhinoconjunctivitis, the symptomatic treatment of perennial allergic rhinoconjunctivitis and the treatment of urticaria. All the embodiments disclosed above for the composition of the first aspect of the invention also apply for its use.
- the X-ray powder diffractogram has been obtained by using an X-ray diffractometer with Cu Ko radiation (1.5418 A) in a PANalytical X'Pert PRO MPD powder diffractometer with a radius of 240 millimeters, in a convergent beam configuration with a focusing mirror and transmission geometry with flat samples inserted between low absorbent films.
- the samples in powder form were inserted between polyester films with a thickness of 3.6microns.
- the diffractograms obtained show the pattern of X-ray powder diffraction (intensity (counts) vs. angle 2-theta (°)).
- Particle Type Non-spherical
- Feed hoper 0.5L
- Tablets were dispersed in water (approx. 1 :5 w/v ratio) and shaken manually for 2 minutes to dissolve the soluble contents in water. The mixture was centrifuged for 1 min at 5000 rpm. The supernatant containing soluble ingredients was discarded. Sample from the sediment was dried, mounted on glass slide, and observed under microscope for particle size analysis. The API and tablet samples were subjected to similar sample preparation and analyzed.
- Particle size of API in the tablets was determined with a pre-calibrated stage micrometer using optical/polarized hot stage microscope (Leica DMLP, Leica, Germany) equipped with a controlled heating and cooling stage (LTS350, Linkam) and an imaging system (VTO 232, JVC - Digital camera and Linksys 32 imaging software, Linkam, England). A small amount of powder was mounted on glass slide and observed under the microscope in dry state. Sample was observed at 500X magnification with a least count of 3.5 micron.
- API particles were differentiated from other ingredients present in tablets through microscopy. This was done based on difference in the melting point of the drug and excipients. API particles could be differentiated by hot-stage microscopy.
- Particle size of API was recorded by measuring the length along the longest axis of individual particles. PSD of separated individual API particles was measured and aggregated API particles were not considered for measurement. Particle size of about 300 particles was determined and data was grouped into class intervals.
- compositions of the invention are 1.1. Compositions of the invention
- Comparative Example 1 defined in Table 2 was prepared following the general process 1 as defined below using the ingredients and the amounts specified in the table, but further comprises a previous step which comprises micronizing the bilastine crystaline form I until having the D90 about 6.8 pm.
- the micronization process of the bilastine was also disclosed herein below.
- the process comprises performing the following 5 consecutive steps: 1) Pre-blending, 2) Screening, 3) Blending, 4) Lubrication and 5) Tableting.
- Pre-blending and screening steps were performed manually at laboratory scale; blending and lubrication steps were performed in a double cone mixer; and tableting step was performed in an eccentric tableting machine.
- step 2 Screening Step.
- the pre-mixture obtained in step 1 and the remaining excipients (including the remaining quantity of the filler) except for the lubricant were screened by a 1000 pm sieve.
- step 3 Blending Step.
- the pre-mixture obtained in step 2) and the excipients (including the remaining quantity of the filler) except for the lubricant were added to a 1L double cone blender and the resulting mixture was mixed during 20 minutes at 18 rpm.
- step 5 Tableting Step.
- the lubricated mixture obtained in step 4) was tableted in an eccentric tableting machine to obtain biconvex and unscored roundimmediate release tablets.
- Example 2 The orodispersible composition of the invention (Example 2) defined in Table 1 was prepared following the general process 2 as defined below using the ingredients and the amounts specified in the table.
- Comparative Example 2 the comparative orodispersible tablet (Comparative Example 2) defined in Table 2 was prepared following the general process 2 as defined below using the ingredients and the amounts specified in the table, but further comprises a previous step which comprises micronizing the bilastine crystal ine form I until having the the D90 about 6.8 pm.
- the micronization process of the bilastine was also disclosed herein below.
- the process comprises perfomring the following 5 consecutive steps: 1) Pre-blending, 2) Screening, 3) Blending, 4) Lubrication and 5) Tableting.
- Pre-blending and screening steps were performed manually at laboratory scale; blending and lubrication steps were performed in a double cone mixer; and tableting step was performed in an eccentric tableting machine.
- Pre-blending Step Two pre-mixtures were performed. The first pre-mixture was prepared by manually premixing the flavour, the sweetener and a part of the filler (10.6% of the total quantity of the filler); and the second pre-mixture was prepared by manually premixing Bilastine (10mg), Crospovidone and a second part of the filler (44.8% of the total quantity of the filler).
- step 3 Blending Step.
- the two pre-mixtures obtained in step 2) and the screened excipients (including the remaining quantity of the filler) except for the lubricant were added to a 1L drum blender and mixed during 20 minutes at 23-24 rpm.
- step 5 Tableting Step.
- the lubricated mixture obtained in step 5) was tableted in an eccentric tableting machine to obtain biconvex and unscored round orodispersible tablets.
- Table 4 shows the percentage of bilastine released from the inmediate release tablets of Examples 1 and 3, and from the commercially available inmediate release tablet of comparative Example 1, expressed as % by weight of bilastine dissolved in the time given.
- Table 5 shows the percentage of bilastine released from the orodispersible tablet of Example 2, and from the commercially available orodispersible tablet of comparative Example 2, expressed as % by weight of bilastine dissolved in the time given.
- compositions of the present invention comprising a therapeutically effective amount of non-micronized bilastine in combination with a pyrrolidone-based polymer has comparable target dissolution profile as commercially available Bilaxten containing micronized bilastine.
- target dissolution profile of the inmediate release bilastine composition comprises at least 85% dissolution at 15 minutes.
- target dissolution profile of the orodispersible tablet bilastine composition comprises at least 85% dissolution at 15 minutes.
- compositions of the present invention allows controlling the release of the non-micronized bilastine having the appropriate dissolution rate and availability for being used in therapy and considered equivalent to commercially available Bilaxten which include micronized bilastine. Furthermore, the use of the combination of non-micronized bilastine in combination with a pyrrolidone-based polymer avoids the disadvantages of processability of micronized active ingredients.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a composition comprising a therapeutically effective amount of bilastine having a particle size distribution D90 from 15 to 90 µm measured by laser diffraction; and a pyrrolidone- based polymer; together with one or more pharmaceutically acceptable excipients or carriers; and a process for its preparation. It also relates to the use of the composition in the treatment of histamine-mediated disease processes and allergic reactions.
Description
A non-micronized bilastine composition
This application claims the benefit of European Patent Application EP20383149.0 filed december 23rd, 2020.
The present invention relates to a novel composition comprising non-micronized bilastine, a preparation process thereof and the use of the composition in the treatment of histamine-mediated disease processes and allergic reactions.
Background Art
Bilastine is the international common name of 4-[2-[4-[1 -(2-ethoxyethyl)-1 h-benzimidazol-2-yl]-1 - piperidinyl)ethyl]-o,a-dimethyl-benzeneacetic acid, whose structure corresponds to the compound of formula (I):
Bilastine is a selective H1 receptor antagonist, meaning that it is useful for treating histamine-mediated disease processes and allergic reactions, and especially for treating rhinoconjunctivitis and urticaria.
Bilastine as a product perse, as well as the preparation and use thereof as an H1 receptor antagonist has been described in the European patent number EP0818454B1 . Subsequently, the European patent EP1505066B1 describes three crystalline forms of bilastine. Specifically, it describes the crystalline forms 1, 2 and 3 of bilastine, which are characterized by the infrared absorption spectrum and crystallographic parameters in the case of form 1. Furthermore, in the patent EP1505066B1 , preparation methods of crystalline form 1 from a mixture of crystalline forms 2 and 3 are described. However, crystalline forms 2 and 3 of bilastine are easily converted into crystalline form 1. Finally, the European patent application EP16829901 A1 describes other crystalline forms of bilastine including Eta crystalline form which is characterized by X-ray diffractogram.
Bilastine is actually present in the market with the commercial drug name Bilaxten, which is in form of inmediate-release and orodispersible tablets. Particularly, Bilaxten contains crystalline form 1 of bilastine in micronized form, having a particle size distribution D90 about 6.8 pm.
As it is known, the different solid forms of a pharmaceutical active ingredient may have different
characteristics and offer certain advantages, for example, with respect to stability, bioavailability, ease of the formulation and ease of administration, among others. Since some solid forms are more suitable for one type of formulation, and other forms for other different formulations, the development of novel solid forms makes it possible to improve the characteristics of pharmaceutical formulations that comprise them. Furthermore, depending on therapeutic indications, one or another pharmaceutical formulation may be preferable.
However, the particle size of the active ingredient may be also critical for having the appropriate dissolution profile and bioavailabilty. In fact, a reduction of the particle size of the active ingredient may be advantegeous for increasing its therapeutic efficacy. Micronization is the process of reducing the average diameter of a solid material's particles. For the purpose of the invention, the term micronization refers to the reduction of average particle diameters to the micrometer range.
Traditional techniques for micronizing based on friction have been widely disclosed in the state of the art. Such traditional methods include milling, bashing and grinding. Methods like crushing and cutting are also used for reducing particle diameter, but produce more rough particles compared to the two previous techniques and are therefore used as the early stages of the micronization process.
Subsequently, modern methods using supercritical fluids in the micronization process has been disclosed. These methods induce a state of supersaturation, which leads to precipitation of individual particles. The most widely applied techniques of this category include the RESS process (Rapid Expansion of Supercritical Solutions), the SAS method (Supercritical Anti-Solvent) and the PGSS method (Particles from Gas Saturated Solutions). These modern techniques allow greater tuneability of the process. In fact, parameters like relative pressure and temperature, solute concentration, and antisolvent to solvent ratio can be varied to be adjusted to the producer's needs. The supercritical fluid methods result in finer control over particle diameters, distribution of particle size and consistency of morphology. However, the properties of the micronized active ingredient such as particle size, size distribution, shape, surface properties, and agglomeration behaviour and powder flow are affected by the type of micronization technique used.
Furthermore, the use of micronized active ingredients for the preparation of solid pharmaceutical compositions entails some processability problems. The first problems is related to wettability and reagglomeration by electrostatic phenomena. In particular, when a mixture containing micronized active ingredients is compressed into tablets, there is a possibility of agglomeration of the micronized particles together within the tablet due to their high surface area and high surface free energy during compression; and also a modification of the physical and chemical properties of the ingredients including the active ingredients and the excipients or carriers. In particular, a change of the polymorphisms of the active ingredient may occur during the micronization process or during its compression, resulting in a possible modification of crucial bioavailability properties (such as stability, dissolution and absorption). And, the second problem is that micronization processes employ higher financial resources and therefore their production is more costly, due to an extra process needed to obtain the desired particle size, affecting the yield and generating more problems from a security and process control point of view.
Therefore, from what is known in the art it is derived that there is still the need of providing compositions comprising non-micronized bilastine having the apropriate dissolution rate and bioavailability by an easy industrially-scaling up and reproducible process.
Summary of Invention
The inventors have surprinsingly found that a composition comprising a therapeutically effective amount of non-micronized bilastine in combination with a pyrrolidone-based polymer, allows having comparable pharmacokinetic parameters on bioavailability (e.g. Cmax, AUCo-t, AUCo-~, AUCO-T.SS, Cmax, ss, and Cmin. ss) as commercially available Bilaxten containing bilastine micronized.
In particular, as it is demonstrated in the Experimental data, the composition of the invention which comprises the combination of a therapeutically effective amount of bilastine having a particle size distribution D90 from 15 to 90 pm with a pyrrolidone-based polymer allows having the appropriate dissolution rate and availability for being used in therapy and being considered equivalent to Bilaxten which contains micronized bilastine.
Furthermore, the compositions of the present invention containing non-micronized bilastine can be prepared by a costless, simple, industrially scale-up and reproducible method without the processability problems disclosed in the state of the art associated to the use of micronized active ingredients (such as wettability and reagglomeration by electrostatic phenomena).
Thus, a first aspect of the invention relates to a composition comprising: a therapeutically effective amount of bilastine having a particle size distribution D90 from 15 to 90 pm measured by laser diffraction; and a pyrrolidone-based polymer; together with one or more pharmaceutically acceptable excipients or carriers.
The second aspect of the invention relates to a preparation process of the composition of the first aspect of the invention.
The third aspect of the invention relates to the use of the composition of the first aspect of the invention in the treatment of histamine-mediated disease processes and allergic reactions.
Brief Description of Drawings
FIG. 1 pattern of X-ray powder diffraction (intensity (counts) vs. angle 2-theta (°)) of crystalline form Eta of bilastine.
FIG. 2 pattern of X-ray powder diffraction (intensity (counts) vs. angle 2-theta (°)) of crystalline form 1 of bilastine.
Detailed description of the invention
All terms as used herein in this application, unless otherwise stated, shall be understood in their ordinary meaning as known in the art. Other more specific definitions for certain terms as used in the present application are as set forth below and are intended to apply uniformly throughout the specification and claims unless an otherwise expressly set out definition provides a broader definition.
For the purposes of the present invention, any ranges given include both the lower and the upper end-points of the range. Ranges given, such as temperatures, times, weights, and the like, should be considered approximate, unless specifically stated. The term "about" or "around” as used herein refers to a range of values ± 10% of a specified value. For example, the expression "about 15" includes ± 10% of 15, i.e. from 13.5 to 16.5.
The terms "percentage (%) by weight”, "weight/weight %” and “w/w%” have the same meaning and are used interchangeable. They refer to the percentage of each ingredient of the composition in relation to the total weight of the composition.
As it is mentioned above, the composition comprises a therapeutically effective amount of bilastine having a particle size distribution D90 from 15 to 90 m. A "therapeutically effective amount” of bilastine relates to the amount of bilastine that provides a therapeutic effect after the administration thereof. In an embodiment, the therapeutically effective amount of bilastine is from about 5 to 50 mg, particularly from about 10 to 40 mg, particularly from about 10 to 30 mg and particularly from about 10 to 20 mg.
The bilastine in the compositions of the invention is not micronized, and particular, the particle size distribution D90 of bilastine is from about 15 to 90 pm. In an embodiment, the particle size distribution D90 of bilastine is from about 25 to 80 pm, particularly from about 25 to 75 pm. The term "particle size” refers to the size of the particles measured in pm. The measurement was performed with an appropriate apparatus by conventional analytical techniques such as, for example, laser diffraction. In the present invention the particle size was measured by a Mastersizer 3000 particle size analyzer. Such apparatus uses a technique of laser diffraction to measure the size of particles. It operates by measuring the intensity of light scattered, as a laser beam passes through a dispersed particles sample. This data is then analyzed using the general purpose model to calculate the size of the particles that created the scattering pattern, assuming a spherical particle shape. Optionally, also microscopic determination utilizing a scanning electron microscope (SEM) may be used. But laser diffraction is preferred.
The terms "particle size distribution” or "PSD” have the same meaning and are used interchangeably. They refer to the percentage of the particles within a certain size range. The term "D90” refers to the value of particle size distribution where at least 90% of the particles have a size less or equal to the given value.
Further, the term "D50” refers to the value of particle size distribution where at least 50% of the particles have a size less or equal to the given value. Thus, for the purpose of the invention, a particle size distribution D90 from about 15 to 90 m means that the 90% of the particles of bilastine have a size less or equal to the given value within the range from about 15 to 90 pm.
The composition of the invention also comprises a pyrrolidone-based polymer. The term "pyrrolidone-based polymer” means that the chemical structure of the monomer of the backbone of the polymer, from which the pyrrolidone-based polymer is made, contains a pyrrolidone. For the purpose of the invention, a "pyrolidonebased polymer” refers to a polymer that comprises more than 50% by weight of polymerized pyrrolidone units (also named monomer).
In an embodiment, the composition is one wherein the pyrrolidone-based polymer comprises 1 -vinyl-2- pyrrolidone units, which mean that the pyrrolidone-based polymer is a polyvinylpyrrolidone. The terms “polyvinylpyrrolidone”, “polyvidone”, “povidone” and “PVP” have the same meaning and they are used interchangeable. In particular, the polyvinylpyrrolidone is the polymer made from the monomer N- vinylpyrroiidone. Polyvinylpyrrolidone is the common name of the compound 1-ethenylpyrrolidin-2-one with the CAS number 9003-39-8 having the following structure:
In an embodiment, the composition is one wherein the pyrrolidone-based polymer is a cross-linked polyvinylpyrrolidone. The terms “cross-linked polyvinylpyrrolidone”, “polyvinylpolypyrrolidone”, “polyvinyl polypyrrolidone”, “PVPP”, “crospovidone” and “crospolividone” have the same meaning and they are used interchangeable. In particular, the crospovidone is a crosslinked polymer made from the monomer N- viny Ipy rrolidone. Crospovidone is the common name of the crosslinked polyvinylpyrrolidone (PVP) named crosslinked 1 -ethenylpyrrolidin-2-one with has the CAS number 25249-54-1.
The terms “cross-linked” or “cross-linking” refers to the use of cross-links to promote a difference in the physical properties of the polymers. The term “cross-links” refers to bonds that link one polymer chain to another or differents parts of the same polymer and these bonds can be covalent or ionic bonds. The term “cross-linker” or “cross-linking agent” refers to compounds having the ability to cross-link the polymer chains. In the present invention, the term “percentage of crosslinking” refers to the amount of cross-links present in the polymer. In an embodiment, the pyrrolidone-based polymer may be any cross-linked polyvinylpyrrolidone with any percentage of crosslinking as measured by ASTM D2765 or by ASTM F2214.
In an embodiment, the composition comprises from 1 to 10 % by weigth of the pyrrolidone-based polymer. In an embodiment, the composition comprises from 1 and 8 % by weigth of the pyrrolidone-based polymer. In an embodiment, the composition comprises from 2 and 8 % by weigth of the pyrrolidone-based polymer. In an embodiment, the composition comprises from 3 and 5 % by weigth of the pyrrolidone-based polymer.
In an embodiment, the composition comprises bilastine having an X-ray diffractogram that comprises characteristic peaks at 8.4; 9.6; 12.2; 13.2; 15.1; and 19.2 ± 0.2 degrees 2 theta measured with an X-ray diffractometer with Cu Ko radiation (1.5418 A) called crystalline Eta form of bilastine. In an embodiment, the composition comprises Eta crystalline form of bilastine which further contains characteristic peaks at 19.7; 20.3; 21 .5; and 23.4 ± 0.2 degrees 2 theta measured with an X-ray diffractometer with Cu Ko radiation
(1.5418 A). In an embodiment, the composition comprises Eta crystalline form of bilastine which further also contains peaks at 14.0; 16.8; 17.5; 18.2 and 25.5 ± 0.2 degrees 2 theta measured with an X-ray diffractometer with Cu Ko radiation (1.5418 A). In an embodiment, the composition comprises Eta crystalline form of bilastine having the X-ray diffractogram shown in FIG. 1.
In an embodiment, the composition comprises Eta crystalline form of bilastine characterized in that it shows the pattern of peaks, expressed in units of 2 theta degrees, 20 (°), in the X-ray powder diffractogram shown in the following table:
The Eta crystalline form of bilastine is prepared following the processes disclosed in the European patent application EP16829901. In an embodiment, the process for the preparation of the Eta crystalline form of bilastine comprising transforming the form 1 of bilastine into the Eta crystalline form, which comprises dispersing crystalline form 1 in water during the time needed for the transformation into the Eta crystalline form of bilastine of said dispersion to take place.
In an embodiment, the composition comprises bilastine having an X-ray diffractogram that comprises characteristic peaks at 12.51; 16.35; 17.24, 19.99 and 21.20 ± 0.2 degrees 2 theta measured with an X-ray diffractometer with Cu Ko radiation (1.5418 A) called crystalline Form I of bilastine. In an embodiment, the composition comprises crystalline Form I of bilastine which further contains characteristic peaks at 10.65; 12.64, 15.58 and 25.00 ± 0.2 degrees 2 theta measured with an X-ray diffractometer with Cu Ko radiation (1.5418 A). In an embodiment, the composition comprises crystalline Form I of bilastine which further also contains peaks at 14.14, 14.33, 1 .48, 23.40 ± 0.2 degrees 2 theta measured with an X-ray diffractometer with Cu Ko radiation (1.5418 A). In an embodiment, the composition comprises crystalline Form I of bilastine having the X-ray diffractogram shown in FIG. 2.
In an embodiment, the composition comprises crystalline Form I of bilastine characterized in that it shows the pattern of peaks, expressed in units of 2 theta degrees, 20 (°), in the X-ray powder diffractogram shown in the following table:
The crystalline form I of bilastine is prepared following the processes disclosed in the European patent EP1505066B1. In an embodiment, the process for the preparation of the crystalline Form 1 of bilastine comprises dispersing crystalline form 1 in water during the time needed for the transformation into the Eta crystalline form of bilastine of said dispersion to take place.
The composition of the present invention comprise one or more pharmaceutically acceptable excipients or carriers. The term "pharmaceutically acceptable excipients or carriers” refers to that excipients or carriers suitable for use in the pharmaceutical technology for preparing compositions with medical use. Said excipients or carriers must be pharmaceutically acceptable in the sense that they must be compatible with the rest of the ingredients of the pharmaceutical composition. They must also be suitable for use in contact with human or animal tissues or organs without showing excessive toxicity, irritation, allergic response, immunogenicity or other problems or complications relating to a reasonable risk/benefit ratio.
The compositions of the invention can be formulated in any form that includes any single unit dosage form and any multiple unit dosage forms. The term "single unit” encompasses one entity such as a single tablet, a single granule, and a single pellet. The term "single unit dosage form” defines a dosage form which consists only of one unit which contains the effective amount of bilastine. The term "multiple unit dosage form” defines a dosage from which consists of more than one unit which contains the effective amount of bilastine. Usually, the multiple unit dosage forms are based on subunits such as granules, pellets or minitablets. They are usually delivered in hard capsules or transformed into tablets. Thus, it is also part of the invention a unit dosage form which comprises the composition of the present invention. In an embodiment, the unit dosage from which comprises the composition of the present invention is a single unit dosage form. In an embodiment, the unit dosage from which comprises the composition of the present invention is a multiple unit dosage form. The appropriate excipients and/or carriers, and their amounts, can readily be determined by those skilled in the art according to the type of formulation being prepared.
In an embodiment, the pharmaceutically acceptable excipients or carriers are selected from the group consisting of selected from the group consisting of diluent, lubricant, binder, glidant, disintegrant and mixtures thereof.
The terms "filler" and "diluent" have the same meaning and are used interchangeably. They refer to any pharmaceutically acceptable excipient or carrier (material) that fill out the size of a composition, making it practical to produce and convenient for the consumer to use. Materials commonly used as filler include calcium carbonate, calcium phosphate, dibasic calcium phosphate, tribasic calcium sulfate, calcium carboxymethyl cellulose, cellulose, cellulose products such as microcrystalline cellulose and its salts, dextrin derivatives, dextrin, dextrose, fructose, lactitol, lactose, starches or modified starches, magnesium carbonate, magnesium oxide, maltitol, maltodextrins, maltose, mannitol, sorbitol, starch, sucrose, sugar, xylitol, erythritol and mixtures thereof. In an embodiment, the composition of the invention is one wherein the pharmaceutically
acceptable excipients or carriers comprises one or more fillers. In an embodiment, the composition of the invention is one wherein the pharmaceutically acceptable excipients or carriers comprises one or more fillers selected from the group consisting of microcrystalline cellulose or sugar alcohols like mannitol. In an embodiment, the composition of the invention is one wherein the pharmaceutically acceptable excipients or carriers comprise one or more filler in an amount from about 35 to 90% by weight of the composition, particularly from about 50 to 90% by weight of the composition, particularly from about 70 to 90% by weight of the composition.
The term "lubricant" refers to a substance that prevents composition ingredients from clumping together and from sticking to the tablet punches or capsule filling machine and improves flowability of the composition mixture. Materials commonly used as a lubricant include sodium oleate, sodium stearate, sodium benzoate, sodium stearate, sodium chloride, stearic acid, sodium stearyl fumarate, calcium stearate, magnesium stearate, magnesium lauryl sulfate, sodium stearyl fumarate, sucrose esters or fatty acid, zinc, polyethylene glycol, talc and mixtures thereof. The presence of a lubricant is particularly preferred when the composition is a tablet to improve the tableting process. In an embodiment, the composition of the invention is one wherein the pharmaceutically acceptable excipients or carriers comprises one or more lubricants selected from the group consisting of magnesium stearate, ascorbic acid and sodium stearyl fumarate. In an embodiment, the composition of the invention is one wherein the pharmaceutically acceptable excipients or carriers comprise one or more lubricants in an amount from 0.1 to 5% by weight of the composition, particularly from 0.5 to 5% by weight of the composition, particularly from about 0.5 to 3% by weight of the composition.
The term "binder” refers to any pharmaceutically acceptable compound having binding properties. Materials commonly used as binders include povidone such as polyvinylpyrrolidone K30, ethyl cellulose polymers, methylcellulose polymers, hydroxyethyl cellulose, hydroxypropyl cellulose, L-hydroxypropyl cellulose (low substituted), hydroxypropylmethyl cellulose (HPMC), sodium carboxymethyl cellulose, carboxymethylene, carboxymethylhydroxyethyl cellulose and other cellulose derivatives, starches or modified starches and mixture thereof. In an embodiment, the composition of the invention is one wherein the pharmaceutically acceptable excipients or carriers comprise one or more binders. In an embodiment, the composition of the invention is one wherein the pharmaceutically acceptable excipients or carriers comprise one or more binders selected from the group consisting of polyvinylpyrrolidone, ethyl cellulose and hydroxypropylmethyl cellulose. In an embodiment, the composition of the invention is one wherein the pharmaceutically acceptable excipients or carriers comprise one or more binders in an amount from 0 to 10% by weight of the composition, particularly from 1 to 10% by weight of the composition, particularly from 1 to 7% by weight of the composition, particularly from about 2.5 to 6% by weight of the composition.
The term "glidant” refers to a substance which improves the flow characteristics of powder mixtures in the dry state. Materials commonly used as a glidant include magnesium stearate, colloidal silicon dioxide or talc. In an embodiment, the composition of the invention is one wherein the pharmaceutically acceptable excipients or carriers comprises one or more glidants. In an embodiment, the composition of the invention is one wherein
the pharmaceutically acceptable excipients or carriers comprises one or more glidants selected from the group consisting of colloidal silicon dioxide and talc. In an embodiment, the composition of the invention is one wherein the pharmaceutically acceptable excipients or carriers comprise one or more glidants in an amount from 0 to 5% by weight of the composition, particularly from 0.1 to 5% by weight of the composition, particularly from 0.2 to 5% by weight of the composition, particularly from about 0.5 to 3% by weight of the composition.
The term “disintegrant” refers to a substance that expand and dissolve when wet causing the tablet to break apart in the body and release the active ingredient for absorption. Materials commonly used as disintegrants include cross-linked polymers like, for example, crospovidone and croscarmellose sodium, and modified starches like sodium starch glycolate.
In an embodiment, the composition of the invention is one wherein the pharmaceutically acceptable excipients or carriers further comprises at least one or more disintegrants differents from pyrrolidone-based polymer. In an embodiment, the composition of the invention is one wherein the pharmaceutically acceptable excipients or carriers comprises at least one disintegrant different from a pyrrolidone-based polymer selected from the group consisting of croscarmellose and sodium starch glycolate. In an embodiment, the composition of the invention is one wherein the pharmaceutically acceptable excipients or carriers comprise one or more disintegrants different from a pyrrolidone-based polymer in an amount from 0 to 10, particularly from 0 to 5% by weight, particularly from about 0.1 to 5 % by weight of the composition.
Additionally, the composition of the present invention may contain other ingredients, such as colorants, sweeteners, aromas, and other components known in the state of the art for use in solid formulations.For example, sweeteners may be selected from the group consisting of sucralose, acesulfame K, aspartame, neohesperidin and dihydrochalcone. Aromas may be selected from the group consisting of grape aroma, strawberry aroma and raspberry aroma.
In an embodiment, the composition of the present invention comprises: a therapeutically effective amount of bilastine having a particle size distribution D90 from 15 to 90 pm; and from 1 to 10 % by weight of a pyrrolidone-based polymer, particularly crospovidone; from 35 to 90 % by weight of a filler; from 0 to 5 % by weight of a glidant; from 0 to 10 % by weight of binder; from 0 to 10 % by weight of a disintegrant different from a pyrrolidone-based polymer; from 0.1 to 5 % by weight of a lubricant; and optionally other pharmaceutically acceptable excipients or carriers; being the sum of the components up to 100% by weight of the composition.
In an embodiment, the composition of the present invention is in a form of tablet.
In an embodiment, the composition of the present invention is form of a tablet and comprises: a therapeutically effective amount of bilastine having a particle size distribution D90 from 15 to 90 pm; and from 1 to 10 % by weight of a pyrrolidone-based polymer, particularly crospovidone; from 35 to 90 % by weight of a filler; from 0 to 5 % by weight of a glidant; from 0 to 10 % by weight of binder; from 0 to 10 % by weight of a disintegrant different from a pyrrolidone-based polymer; from 0.1 to 5 % by weight of a lubricant; and optionally other pharmaceutically acceptable excipients or carriers; being the sum of the components up to 100% by weight of the composition.
In an embodiment the composition of the present invention is in a form of immediate release tablet and an orodispersible tablet (abbreviated as ODT).
In an embodiment, the composition of the present invention is in a form immediate release tablet. For the purpose of the invention, the term "immediate release” composition refers to a composition which releases the active ingredient substantially immediately upon contact with gastric juices and will result in substantially complete dissolution within about 1 hour. Immediate release (IR) components can also be referred to as instant release. When used in association with the dissolution profiles discussed herein, the term "immediate release” refers to the composition which delivers the active ingredient over a period of time less than 1 hour.
In an embodiment, the composition of the present invention is in form of an immediate release tablet comprising: a therapeutically effective amount of bilastine having a particle size distribution D90 from 15 to 90 pm; and from 1 to 10 % by weight of a pyrrolidone-based polymer, particularly crospovidone; from 35 to 90 % by weight of a filler; from 0.1 to 5 % by weight of a glidant; from 0.1 to 5 % by weight of a lubricant; and optionally other pharmaceutically acceptable excipients or carriers; being the sum of the components up to 100% by weight of the composition.
In an embodiment, the composition of the present invention is in form of an immediate release tablet comprising: a therapeutically effective amount of bilastine having a particle size distribution D90 from 15 to 90 pm; and from 2 to 8 % by weight of a pyrrolidone-based polymer, particularly crospovidone; from 50 to 90 % by weight of a filler; from 0.2 to 5 % by weight of a glidant; from 0.5 to 5 % by weight of a lubricant; and
optionally other pharmaceutically acceptable excipients or carriers; being the sum of the components up to 100% by weight of the composition
In an embodiment, the composition of the present invention is in form of an immediate release tablet comprising: a therapeutically effective amount of bilastine having a particle size distribution D90 from 15 to 90 pm; and from 3 to 5 % by weight of a pyrrolidone-based polymer, particularly crospovidone; from 70 to 90 % by weight of a filler; from 0.5 to 3 % by weight of a glidant; from 0.5 to 3 % by weight of a lubricant; and optionally other pharmaceutically acceptable excipients or carriers; being the sum of the components up to 100% by weight of the composition
In an embodiment, the composition is in form of a orodispersible tablet (ODT). The terms “orodispersible” tablet, "quick disintegrating” tablet, "mouth dissolving” tablet, "porous” tablets and the abbreviature "ODT” have the same meaning and they can be used interchangeable. In particular, the term "orodispersible” tablet refers to non-coated tablets for placing in the mouth which disintegrate quickly before they are swallowed. In particular, it is established that the time under which they must disintegrate in the disintegration test for tablets and capsules, according to the Ph. Eur. 2.9.1. is 3 minutes (cf. European Pharmacopoeia (Ph.Eur.) 5th edition, Supplement 5.2, published in June 2004). The orodispersible tablet of the present inventionis advantageously used in cases where administration without water is necessary, cases of administration to patients who have difficulty in swallowing tablets, or cases of administration to the elderly or to children where there is a fear of blocking the throat if it is unusual tablet form.
In an embodiment, the composition of the present invention is in form of an orodispersible tablet comprising: a therapeutically effective amount of bilastine having a particle size distribution D90 from 15 to 90 pm; and from 1 to 10 % by weight of a pyrrolidone-based polymer, particularly crospovidone; from 35 to 90 % by weight of a filler; from 1 to 10 % by weight of a binder; from 0.1 to 5 % by weight of a lubricant; and optionally other pharmaceutically acceptable excipients or carriers; being the sum of the components up to 100% by weight of the composition.
In an embodiment, the composition of the present invention is in form of an orodispersible tablet comprising: a therapeutically effective amount of bilastine having a particle size distribution D90 from 15 to 90 pm; and from 2 to 8 % by weight of a pyrrolidone-based polymer, particularly crospovidone; from 50 to 90 % by weight of a filler; from 1 to 7 % by weight of a binder; from 0.5 to 5 % by weight of a lubricant; and
optionally other pharmaceutically acceptable excipients or carriers; being the sum of the components up to 100% by weight of the composition.
In an embodiment, the composition of the present invention is in form of an orodispersible tablet comprising: a therapeutically effective amount of bilastine having a particle size distribution D90 from 15 to 90 pm; and from 3 to 5 % by weight of a pyrrolidone-based polymer, particularly crospovidone; from 70 to 90 % by weight of a filler; from 2.5 to 6 % by weight of a binder; from 0.5 to 3 % by weight of a lubricant; and optionally other pharmaceutically acceptable excipients or carriers being the sum of the components up to 100% by weight of the composition.
It is also part of the invention, a process for the preparation of the compositions in form of tablets of the invention. In an embodiemnt, the process for the preparation of the immediate release tablets of the present invention comprises: a) preparing a pre-mixture comprising bilastine or a pharmaceutically acceptable salt thereof, Crospovidone and a part of the filler (particularly about 20% of the total amount of the filler); f) optionally, sieving the pre-mixture obtained in step a) and each one of the remaining excipients (including the remaining quantity of the filler) separately by a sieve having a sieve diameter from 750 to 1250 pm; b) mixing the pre-mixture obtained in step a) with the remaining excipients including the crospovidone and except for the lubricant; c) adding the lubricant to the mixture obtained in step b); and d) compressing the mixture obtained in step (c) to form tablets; and (e) optionally, coating the tablets obtained in step (d).
In an embodiment, the process for the preparation of the orodispersible tablets of the present invention comprises: a') preparing a first pre-mixture comprising the flavour, the sweetener and a part of the filler (particularly about 10% of the total amount of the filler); a”) preparing a second pre-mixture comprising bilastine or a pharmaceutically acceptable salt thereof, Crospovidone and a part of the remaining part of the filler (particularly about 40-50% of the total amount of the filler); f) optionally, sieving the first and the second pre-mixture obtained in step a') and a”), and each one of the remaining excipients (including the remaining quantity of the filler) separately by a sieve having a sieve diameter from 750 to 1250 pm; b') mixing the first and the second pre-mixture with the remaining excipients including the crospovidone the remaining quantity of the filler and except for the lubricant; c') adding the lubricant to the mixture obtained in step b’); and d') compressing the mixture obtained in step (c') to form tablets; and (e') optionally, coating the tablets
obtained in step (d’).
In an embodiment, each one of the steps (a), (a') and (a”) of the process for preparation of the composition of the invention is performed at room temperature. In an embodiment, each one of the steps (a), (a') and (a”) of the process for preparation of the composition of the invention is performed manually at lab step or in a double cone or tumbler mixer at industrial scale.
In an embodiment, each one of the steps (b), (b'), (c) and (c') of the process for preparation of the composition of the invention is performed at room temperature. In an embodiment, each one of the steps (b), (b'), (c) and (c’) of the process for preparation of the composition of the invention is performed in a double cone or tumbler mixer.
In an embodiment, the process comprises step (f) or (f). In an embodiment, each one of steps (f) or (f) are performed by the use of a sieve of 1000 m for sieving the pre-mixtures, mixture and excipients excpet for the lubricant which is sieve throught a sieve of 250 pm of diameter.
In an embodiment, the compressing steps (d) and (d’) of the process for preparation of the composition of the invention is performed using an eccentric tableting machine for lab-scale process and rotary tableting machine for industrial scale. In an embodiment, the compressing steps (d) and (d’) of the process for preparation of the composition of the invention is performed in order to obtain tablets having a hardness about 55 to 95N.
As it is mentioned above, the composition of the invention allows having the appropriate dissolution rate and availability for being used in therapy and considered equivalent to Bilaxten which include micronized bilastine.
In an embodiment, the composition of the invention is an immediate release tablet which exhibits a dissolution profile according to which at least 85% by weight of the bilastine or a pharmaceutically acceptable salt thereof is dissolved in 15 min, wherein: the dissolution profile is measured using a USP type I apparatus (basket), placing the composition in 900mL of phosphate buffer having pH 6.8, at 37°C and 50 rpm.
In an embodiment, the composition of the invention is an orodispersible tablet which exhibits a dissolution profile according to which at least 85% by weight of the bilastine or a pharmaceutically acceptable salt thereof is dissolved in 15 min, wherein: the dissolution profile is measured using a USP type I apparatus (basket), placing the composition in 900mL of phosphate buffer having pH 6.8, at 37°C and 50 rpm. A skilled person must differencials between disintegration (according to the Ph. Eur. 2.9.1. is 3 minutes) and dissolution profile.
In an embodiment, the composition of the invention, exhibits a maximum plasma concentration (Cmax) and an area under the time/plasma concentration curve from time 0 to 36 hours (AUG (0-36)) from 80 to 125% refering to the Bilaxten reference product, in a confidence interval of 90% . The term "Cmax" refers to the maximum concentration of bilastine in the blood following a single-dose administration of the composition.
The term "AUG" refers to the area under the time/plasma concentration curve after an oral single-dose administration of the composition of the present invention. AUCO-infinity denotes the area under the plasma concentration versus time curve from time 0 to infinity and AUCo-t denotes the area under the plasma concentration versus time curve from time 0 to time t.
Other aspect of the invention relates to the use of the composition of the invention in treatment of histamine- mediated disease processes and allergic reactions. This aspect could be also formulated as the use of a composition of the invention as defined above for the preparation of a medicament for the prophylaxis and/or treatment of the histamine-mediated disease processes and allergic reactions. It also relates to a method for the prophylaxis and/or treatment of a mammal suffering or is susceptible to suffer from a histamine-mediated disease processes and allergic reactions, wherein the method comprises administering to said mammal an effective amount of the composition of the present invention. In an embodiment, the histamine-mediated disease processes and allergic reactions are selected from the group consisting of the symptomatic treatment of seasonal allergic rhinoconjunctivitis, the symptomatic treatment of perennial allergic rhinoconjunctivitis and the treatment of urticaria. All the embodiments disclosed above for the composition of the first aspect of the invention also apply for its use.
Throughout the description and claims the word "comprise" and variations of the word, are not intended to exclude other technical features, additives, components, or steps. Furthermore, the word "comprise” encompasses the case of "consisting of”. Additional objects, advantages and features of the invention will become apparent to those skilled in the art upon examination of the description or may be learned by practice of the invention. The following examples and drawings are provided by way of illustration, and they are not intended to be limiting of the present invention. Reference signs related to drawings and placed in parentheses in a claim, are solely for attempting to increase the intelligibility of the claim, and shall not be construed as limiting the scope of the claim. Furthermore, the present invention covers all possible combinations of particular and preferred embodiments described herein.
Examples
Methods:
- X-ray Powder diffractogram (XRPD) method
The X-ray powder diffractogram has been obtained by using an X-ray diffractometer with Cu Ko radiation (1.5418 A) in a PANalytical X'Pert PRO MPD powder diffractometer with a radius of 240 millimeters, in a convergent beam configuration with a focusing mirror and transmission geometry with flat samples inserted between low absorbent films. The samples in powder form were inserted between polyester films with a thickness of 3.6microns.
The experimental conditions were as follows: Cu Ko radiation (a = 1.5418 A).
Working power: 45 kV - 40 mA.
Incident beam slits that define a beam height of 0.4 millimeters
Incident and diffracted beam slits of 0.02 radian Seller
Detector PIXcel: active length = 3.347 °2theta/theta scans of 2 to 40 °2theta with a step size of 0.026 °2theta and a measurement time of 76 seconds per step.
The diffractograms obtained show the pattern of X-ray powder diffraction (intensity (counts) vs. angle 2-theta (°)).
- Determination of the particle size distribution (PSD) of Bilastine by laser diffraction
2mg of sample were taken to measure the PSD of every API sample
Instrument conditions
Instrument: Malvern Laser Diffraction Masterizer 3000
Accesory: Dry Smapler Aero S
Measuring range: 0.001-3500pim
Sensitivity: Normal
Particle Type: Non-spherical
Material Refraction Index: 1.59
Material Absorption Index: 0.01
Dispersant: Air
Dispersant Air Pressure: 2 bar
Background measuring time: 5 seconds
Sample meauring time: 5 seconds
Number of measurements: 3
Obscuration Range: 1-5%
Feed rate: 30%
Hoper opening: 2.5
Micronization method for Bilastine Form I
Wet molturation of sample
Instrument: Pilot micronizer with Jetmill technology Inox 316
Feed hoper: 0.5L
Mirror polish: Ra < 0.2 pm
Dosage speed: 30g/h
Chamber pressure: 2.0 bar
PSD analysis of the commercial tablets Bilaxten by SEM
Tablets were dispersed in water (approx. 1 :5 w/v ratio) and shaken manually for 2 minutes to dissolve the soluble contents in water. The mixture was centrifuged for 1 min at 5000 rpm. The supernatant containing soluble ingredients was discarded. Sample from the sediment was dried, mounted on glass slide, and
observed under microscope for particle size analysis. The API and tablet samples were subjected to similar sample preparation and analyzed.
Particle size of API in the tablets was determined with a pre-calibrated stage micrometer using optical/polarized hot stage microscope (Leica DMLP, Leica, Germany) equipped with a controlled heating and cooling stage (LTS350, Linkam) and an imaging system (VTO 232, JVC - Digital camera and Linksys 32 imaging software, Linkam, England). A small amount of powder was mounted on glass slide and observed under the microscope in dry state. Sample was observed at 500X magnification with a least count of 3.5 micron.
Identification of API
For particle size analysis, API particles were differentiated from other ingredients present in tablets through microscopy. This was done based on difference in the melting point of the drug and excipients. API particles could be differentiated by hot-stage microscopy.
Particle size of API was recorded by measuring the length along the longest axis of individual particles. PSD of separated individual API particles was measured and aggregated API particles were not considered for measurement. Particle size of about 300 particles was determined and data was grouped into class intervals.
1. Compositions
The values of the D90 of the crystalline form of Bilastine used for the preparation of the compositions of Examples 1-3 of the present invention and of the comparative Examples using the method as defined above were disclosed below in each one of the Tables 1 and 2.
1.1. Compositions of the invention
The qualitative and quantitative composition of the immediate release tablets (IR-tablets of Examples 1 and 3) and orodispersible tablets (ODT of Example 2) of the present invention are shown in Table 1, wherein the amount of each of the components are expressed in weight percent:
Table 1
1.2. Comparative compositions
The qualitative and quantitative comparative composition of the commercially available immediate realease tablet of micronized bilastine (Bilaxten) (Comparative Example 1) and the qualitative comparative composition of the commercially available orodispersible tablet of micronized bilastine (Bilaxten) (Comparative Example 2) falling outside the scope of the present invention are shown in Table 2, wherein the amount of each of the components are expressed in weight percent:
Table 2
Table2-cont.
1.3. Preparation process
1.3.1. Immediate release compositions
The immediate release compositions of the invention (Examples 1 and 3) defined in Table 1 were prepared following the general process 1 as defined below using the ingredients and the amounts specified in the table.
Meanwhile, the comparative immediate realease tablet (Comparative Example 1) defined in Table 2 was prepared following the general process 1 as defined below using the ingredients and the amounts specified in the table, but further comprises a previous step which comprises micronizing the bilastine crystaline form I until having the D90 about 6.8 pm. The micronization process of the bilastine was also disclosed herein below.
General process 1
The process comprises performing the following 5 consecutive steps: 1) Pre-blending, 2) Screening, 3) Blending, 4) Lubrication and 5) Tableting. Pre-blending and screening steps were performed manually at laboratory scale; blending and lubrication steps were performed in a double cone mixer; and tableting step was performed in an eccentric tableting machine.
The general process 1 is disclosed herein below.
1) Pre-blending Step. Bilastine (20mg), Crospovidone and a part of the filler (20.6% of the total quantity of the filler) were premixed to obtain a pre-mixture.
2) Screening Step. The pre-mixture obtained in step 1 and the remaining excipients (including the remaining quantity of the filler) except for the lubricant were screened by a 1000 pm sieve.
3) Blending Step. The pre-mixture obtained in step 2) and the excipients (including the remaining quantity of the filler) except for the lubricant were added to a 1L double cone blender and the resulting mixture was mixed during 20 minutes at 18 rpm.
4) Lubricating Step. The lubricant (previously screened by a 250 pm sieve) was added to the mixture obtained in step 3) and mixed for 5 minutes at 18 rpm in the same double cone mixer.
5) Tableting Step. The lubricated mixture obtained in step 4) was tableted in an eccentric tableting machine to obtain biconvex and unscored roundimmediate release tablets.
1.3.2. Orodispersible compositions
The orodispersible composition of the invention (Example 2) defined in Table 1 was prepared following the general process 2 as defined below using the ingredients and the amounts specified in the table.
Meanwhile, the comparative orodispersible tablet (Comparative Example 2) defined in Table 2 was prepared following the general process 2 as defined below using the ingredients and the amounts specified in the table,
but further comprises a previous step which comprises micronizing the bilastine crystal ine form I until having the the D90 about 6.8 pm. The micronization process of the bilastine was also disclosed herein below.
General process 2
The process comprises perfomring the following 5 consecutive steps: 1) Pre-blending, 2) Screening, 3) Blending, 4) Lubrication and 5) Tableting. Pre-blending and screening steps were performed manually at laboratory scale; blending and lubrication steps were performed in a double cone mixer; and tableting step was performed in an eccentric tableting machine.
The process is disclosed herein below.
1) Pre-blending Step. Two pre-mixtures were performed. The first pre-mixture was prepared by manually premixing the flavour, the sweetener and a part of the filler (10.6% of the total quantity of the filler); and the second pre-mixture was prepared by manually premixing Bilastine (10mg), Crospovidone and a second part of the filler (44.8% of the total quantity of the filler).
2) Screening Step. The first and the second pre-mixtures obtained in previous step and the remaining excipients (including the remaining quantity of the filler) except for the lubricant were screened by a 1000 pm sieve.
3) Blending Step. The two pre-mixtures obtained in step 2) and the screened excipients (including the remaining quantity of the filler) except for the lubricant were added to a 1L drum blender and mixed during 20 minutes at 23-24 rpm.
4) Lubricating Step. The lubricant (previously screened by a 250 pm sieve) was added to the mixture obtained in step 3) and mixed for 5 minutes at 23-24 rpm in the same blender.
5) Tableting Step. The lubricated mixture obtained in step 5) was tableted in an eccentric tableting machine to obtain biconvex and unscored round orodispersible tablets.
2. Dissolution Test
The dissolution profile of the compositions of Examples 1-3 of the present invention and the comparative Examples 1 and 2 was measured.
Conditions of the dissolution bath
- Paddle speed: 50 rpm
- Temperature of dissolution medium: 37.0°C ± 0.5°C
- Dissolution Medium: sodium acetate buffer
- Vessel volume: 900 mL
- Vessel pH: 4.5
- Sample volume: 10 mL
-Time point (min): 5, 10, 15, 20 and 30.
-no of units: 1
Method:
To the set dissolution apparatus having a 900mL of dissolution medium as defined above to each of 6 glass vessels and under the above mentioned conditions, a tablet of the test sample was added into each basket lower down hood, taking care to exclude the air bubbles from the surface of the tablet and immediately start the apparatus.
After that, at each time point, 10 mL of the test sample from each of 6 glass vessels were withdrawn and filtered through 0.22pi polyvinylidene fluoride filter (PVDF filter). Further, the withdrawn volume at each time point is replaced by adding an equal quantity of fresh dissolution medium at 37.0°C ± 0.5°C.
Conditions of the chromatographic analysis
- Column: Acquity BEH C18 1.7 pm (100 x 2.1 mm) or equivalent
- Mobile Phase A: Acetonitrile HPLC grade : Methanol HPLC grade (50:50)
- Mobile Phase B: 5 mM Ammonium hydrogen carbonate (pH=10)
Dissolve 0.40 g of ammonium hydrogen carbonate in about 900 mL of water of water, HPLC grade. Stir it until complete dissolution and adjust to pH=10.0 ± 0.5 with 30% ammonium hydroxide. Dilute to 1000 mL with water, HPLC grade and filter through 0.22 pm GHP filter.
- Mobile phase: Mobile Phase A/Mobile Phase B (55:45) (isocratic)
- Flow: 0.4 mL/min
- Column temperature: 30 °C
- Wavelength detection: 220 nm
- Injection volume: 2 pL- Loop: 2 pL
- Sample Loop Option: Full loop
- Sample temperature: Room temperature
- Retention time: Bilastine: aboutl .1 min
- Run time: 2 min
Results
The weight percent of bilastine released from the compositions of Example 1-3 of the present invention and the comparative Examples 1 and 2 submitted to the above-mentioned dissolution conditions at the time points; as well as the relative standard deviation is shown in Tables below.
Table 4 shows the percentage of bilastine released from the inmediate release tablets of Examples 1 and 3, and from the commercially available inmediate release tablet of comparative Example 1, expressed as % by weight of bilastine dissolved in the time given.
Table 4
ND = not determined
Table 5 shows the percentage of bilastine released from the orodispersible tablet of Example 2, and from the commercially available orodispersible tablet of comparative Example 2, expressed as % by weight of bilastine dissolved in the time given.
Table 5
The results of the dissolution profile disclosed in the above-mentioned Tables showed that the compositions of the present invention comprising a therapeutically effective amount of non-micronized bilastine in combination with a pyrrolidone-based polymer has comparable target dissolution profile as commercially available Bilaxten containing micronized bilastine. In particular, the target dissolution profile of the inmediate release bilastine composition comprises at least 85% dissolution at 15 minutes. And, the target dissolution profile of the orodispersible tablet bilastine composition comprises at least 85% dissolution at 15 minutes.
Thus, the compositions of the present invention allows controlling the release of the non-micronized bilastine having the appropriate dissolution rate and availability for being used in therapy and considered equivalent to commercially available Bilaxten which include micronized bilastine. Furthermore, the use of the combination of non-micronized bilastine in combination with a pyrrolidone-based polymer avoids the disadvantages of processability of micronized active ingredients.
Claims
1. A composition comprising: a therapeutically effective amount of bilastine having a particle size distribution D90 from 15 to 90 pm measured by laser diffraction; and a pyrrolidone-based polymer; together with one or more pharmaceutically acceptable excipients or carriers.
2. The composition according to claim 1, wherein the pyrrolidone-based polymer comprises 1-vinyl-2- pyrrolidone units.
3. The composition according to any of the claims 1 or 2, wherein the pyrrolidone-based polymer is a crosslinked 1-vinyl-2-pyrrolidone.
4. The composition according to any of the claims 1-3, which comprises from 1 to 10 % by weigth of the pyrrolidone-based polymer.
5. The composition according to any of the claims 1-4, wherein the particle size distribution D90 is from 25 to 80 pm.
6. The composition according to any of the claims 1-5, wherein the bilastine has an X-ray diffractogram that comprises:
Bilastine crystaline form eta defined by characteristic peaks at 8.4; 9.6; 12.2; 13.2; 15.1; and 19.2 ± 0.2 degrees 2 theta measured with an X-ray diffractometer with Cu Ko radiation (1 .5418 A); or alternatively
Bilastine crystalline form I defined by characteristic peaks at 12.51; 16.35; 17.24, 19.99 and 21.20 ± 0.2 degrees 2 theta measured with an X-ray diffractometer with Cu Ko radiation (1 .5418 A).
7. The composition according to any of the claims 1-6, which is in a form of tablet; particularly selected from the group consisting of an immediate release tablet and an orodispersible tablet.
8. The composition according to any of the claims 1-7, wherein the pharmaceutically acceptable excipients or carriers are selected from the group consisting of selected from the group consisting of diluent, lubricant, binder, glidant, disintegrant and mixtures thereof.
9. The composition according to any of the claims 1-8, which comprises: a therapeutically effective amount of bilastine having a particle size distribution D90 from 15 to 90 pm; and from 1 to 10 % by weight of a pyrrolidone-based polymer, particularly crospovidone;
from 35 to 90 % by weight of a filler; from 0 to 5 % by weight of a glidant; from 0 to 10 % by weight of binder; from 0 to 10 % by weight of a disintegrant different from a pyrrolidone-based polymer; from 0.1 to 5 % by weight of a lubricant; and optionally other pharmaceutically acceptable excipients or carriers; being the sum of the components up to 100% by weight of the composition.
10. The composition according to claim 9, wherein: the composition is in form of an immediate release tablet and the composition comprises: a therapeutically effective amount of bilastine having a particle size distribution D90 from 15 to 90 pm; and from 1 to 10 % by weight of a pyrrolidone-based polymer, particularly crospovidone; from 35 to 90 % by weight of a filler; from 0.1 to 5 % by weight of a glidant; from 0.1 to 5 % by weight of a lubricant; and optionally other pharmaceutically acceptable excipients or carriers; being the sum of the components up to 100% by weight of the composition; or alternatively, the composition is in form of a orodispersible tablet and the composition comprises: a therapeutically effective amount of bilastine having a particle size distribution D90 from 15 to 90 pm; and from 1 to 10 % by weight of a pyrrolidone-based polymer, particularly crospovidone; from 35 to 90 % by weight of a filler; from 1 to 10 % by weight of binder; from 0.1 to 5 % by weight of a lubricant; and optionally other pharmaceutically acceptable excipients or carriers; being the sum of the components up to 100% by weight of the composition.
11. The composition according to any of the claims 1-10, for use in the treatment of histamine-mediated disease processes and allergic reactions.
12. The composition for use according to claim 11, wherein the histamine-mediated disease processes and allergic reactions are selected from the group consisting of the symptomatic treatment of seasonal allergic rhinoconjunctivitis, the symptomatic treatment of perennial allergic rhinoconjunctivitis and the treatment of urticaria.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP20383149 | 2020-12-23 | ||
PCT/EP2021/083930 WO2022135863A1 (en) | 2020-12-23 | 2021-12-02 | A non-micronized bilastine composition |
Publications (1)
Publication Number | Publication Date |
---|---|
EP4267109A1 true EP4267109A1 (en) | 2023-11-01 |
Family
ID=74194484
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP21819492.6A Pending EP4267109A1 (en) | 2020-12-23 | 2021-12-02 | A non-micronized bilastine composition |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP4267109A1 (en) |
CA (1) | CA3200779A1 (en) |
WO (1) | WO2022135863A1 (en) |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2124167B1 (en) | 1996-06-04 | 1999-09-16 | Espanola Prod Quimicos | NEW DERIVATIVES OF BENZMIDAZOLE WITH ANTIHISTAMINE ACTIVITY. |
AU2002255017B2 (en) | 2002-04-19 | 2008-11-13 | Faes Farma, S.A. | Polymorph of 4-[2-[4-[1-(2-ethoxyethyl)-1H-benzimidazole-2-yl]-1-piperidinyl]ethyl]-alpha, alpha-dimethyl-benzeneacetic acid |
CN103356616A (en) * | 2013-06-29 | 2013-10-23 | 北京万全德众医药生物技术有限公司 | Bilastine-containing pharmaceutical composition and preparation method thereof |
CN106606486A (en) * | 2015-10-22 | 2017-05-03 | 天津市汉康医药生物技术有限公司 | Bilastine tablet and preparation method thereof |
-
2021
- 2021-12-02 CA CA3200779A patent/CA3200779A1/en active Pending
- 2021-12-02 EP EP21819492.6A patent/EP4267109A1/en active Pending
- 2021-12-02 WO PCT/EP2021/083930 patent/WO2022135863A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
CA3200779A1 (en) | 2022-06-30 |
WO2022135863A1 (en) | 2022-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6041919B2 (en) | Salt of 8-[{1- (3,5-bis- (trifluoromethyl) phenyl) -ethoxy} -methyl] -8-phenyl-1,7-diaza-spiro [4.5] decan-2-one Tablet formulations containing and tablets made therefrom | |
CA2726472C (en) | Solid pharmaceutical formulations comprising bibw 2992 | |
JP2017039768A (en) | Apixaban formulations | |
EP1957048A2 (en) | Solid orally administerable pharmaceutical dosage forms with rapid active principle release | |
WO2009100176A2 (en) | Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor | |
ES2871175T3 (en) | Immediate-release tablets containing a drug and processes for the formation of the tablets | |
EP2654730A2 (en) | High drug load pharmaceutical formulations comprising dronedarone and its pharmaceutically acceptable salts | |
EP4284344A1 (en) | Pharmaceutical composition | |
JP2010536798A (en) | Method and composition for controlling bioavailability of poorly soluble drugs | |
AU2021281283A1 (en) | Pralsetinib pharmaceutical compositions | |
IL269668B2 (en) | Pharmaceutical compositions comprising (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxy-pyridazin-3-yl)methanol and their preparation | |
EP4267109A1 (en) | A non-micronized bilastine composition | |
JP2023036924A (en) | Pharmaceutical composition containing lenalidomide | |
JP2022540170A (en) | Pharmaceutical preparation | |
EP3072528B1 (en) | Composition comprising vemurafenib and cationic copolymer based on methacrylates | |
KR20210024593A (en) | Formulation comprising a dopamine-β-hydroxylase inhibitor and method for preparing the same | |
WO2004010979A1 (en) | Processes for the preparation of oral dosage formulations of modafinil | |
JP2004210702A (en) | New crystal of 5-[(1z,2e)-2-methyl-3-phenyl-2-propenylidene]-4-oxo-2-thioxo-3-thiazolidineacetic acid, method for producing the same, and pharmaceutical with the same as active ingredient | |
EP3072529A1 (en) | Composition comprising vemurafenib and hpmc-as | |
Aly et al. | Research Paper Preparation and Evaluation of Glipizide Tablets Containing both Enhanced and Sustained Release Solid Dispersions | |
WO2023227997A1 (en) | Pharmaceutical composition containing combination of azilsartan and chlorthalidone and process of preparation thereof | |
WO2023180577A1 (en) | Therapeutic uses of bradykinin b2-receptor antagonists | |
EP2968167A1 (en) | Dosage form comprising crizotinib | |
CN116782888A (en) | Pharmaceutical composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20230724 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) |